GT Biopharma's CFO resigns
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
GT Biopharma Inc. said Steven Weldon resigned as CFO and director of the company, effective Oct. 11.
The Westlake Village, Calif.-based developer of cancer therapies said that Weldon's resignation did not result from any disagreement with the company.
